Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells.

Hou TZ, Qureshi OS, Sansom DM.

Methods Mol Biol. 2019;1899:87-101. doi: 10.1007/978-1-4939-8938-6_7.

PMID:
30649767
2.

Characterization of CTLA4 Trafficking and Implications for Its Function.

Khailaie S, Rowshanravan B, Robert PA, Waters E, Halliday N, Badillo Herrera JD, Walker LSK, Sansom DM, Meyer-Hermann M.

Biophys J. 2018 Oct 2;115(7):1330-1343. doi: 10.1016/j.bpj.2018.08.020. Epub 2018 Aug 23.

PMID:
30219287
3.

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.

Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B.

J Allergy Clin Immunol. 2018 Dec;142(6):1932-1946. doi: 10.1016/j.jaci.2018.02.055. Epub 2018 May 4.

PMID:
29729943
4.

Study of an extended family with CTLA-4 deficiency suggests a CD28/CTLA-4 independent mechanism responsible for differences in disease manifestations and severity.

Hou TZ, Olbrich P, Soto JML, Sanchez B, Moreno PS, Borte S, Stauss HJ, Burns SO, Walker LSK, Pan-Hammarström Q, Hammarström L, Sansom DM, Neth O.

Clin Immunol. 2018 Mar;188:94-102. doi: 10.1016/j.clim.2018.01.001. Epub 2018 Jan 3.

PMID:
29305966
5.

CTLA-4: a moving target in immunotherapy.

Rowshanravan B, Halliday N, Sansom DM.

Blood. 2018 Jan 4;131(1):58-67. doi: 10.1182/blood-2017-06-741033. Epub 2017 Nov 8. Review.

6.

Decreased sensitivity to 1,25-dihydroxyvitamin D3 in T cells from the rheumatoid joint.

Jeffery LE, Henley P, Marium N, Filer A, Sansom DM, Hewison M, Raza K.

J Autoimmun. 2018 Mar;88:50-60. doi: 10.1016/j.jaut.2017.10.001. Epub 2017 Oct 21.

7.

Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.

Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR, Jermutus L.

J Immunol. 2017 Sep 1;199(5):1943. doi: 10.4049/jimmunol.1790013. No abstract available.

8.

Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.

Verma N, Burns SO, Walker LSK, Sansom DM.

Clin Exp Immunol. 2017 Oct;190(1):1-7. doi: 10.1111/cei.12997. Epub 2017 Jul 21. Review.

9.

Thymus transplantation for complete DiGeorge syndrome: European experience.

Davies EG, Cheung M, Gilmour K, Maimaris J, Curry J, Furmanski A, Sebire N, Halliday N, Mengrelis K, Adams S, Bernatoniene J, Bremner R, Browning M, Devlin B, Erichsen HC, Gaspar HB, Hutchison L, Ip W, Ifversen M, Leahy TR, McCarthy E, Moshous D, Neuling K, Pac M, Papadopol A, Parsley KL, Poliani L, Ricciardelli I, Sansom DM, Voor T, Worth A, Crompton T, Markert ML, Thrasher AJ.

J Allergy Clin Immunol. 2017 Dec;140(6):1660-1670.e16. doi: 10.1016/j.jaci.2017.03.020. Epub 2017 Apr 8.

10.

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.

Hou TZ, Verma N, Wanders J, Kennedy A, Soskic B, Janman D, Halliday N, Rowshanravan B, Worth A, Qasim W, Baxendale H, Stauss H, Seneviratne S, Neth O, Olbrich P, Hambleton S, Arkwright PD, Burns SO, Walker LS, Sansom DM.

Blood. 2017 Mar 16;129(11):1458-1468. doi: 10.1182/blood-2016-10-745174. Epub 2017 Feb 3.

11.

Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.

Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M.

J Allergy Clin Immunol. 2017 Mar;139(3):1043-1046.e5. doi: 10.1016/j.jaci.2016.08.042. Epub 2016 Nov 28. No abstract available.

PMID:
27908448
12.

A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.

Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TI, Sansom DM, Bowen MA, Minter RR, Jermutus L.

J Immunol. 2017 Jan 1;198(1):528-537. Epub 2016 Nov 23. Erratum in: J Immunol. 2017 Sep 1;199(5):1943.

13.

1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept.

Gardner DH, Jeffery LE, Soskic B, Briggs Z, Hou TZ, Raza K, Sansom DM.

J Immunol. 2015 Sep 15;195(6):2657-65. doi: 10.4049/jimmunol.1500306. Epub 2015 Aug 14.

14.

IMMUNOLOGY. Moving CTLA-4 from the trash to recycling.

Sansom DM.

Science. 2015 Jul 24;349(6246):377-8. doi: 10.1126/science.aac7888. Epub 2015 Jul 23. No abstract available.

PMID:
26206917
15.

Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.

Jeffery LE, Qureshi OS, Gardner D, Hou TZ, Briggs Z, Soskic B, Baker J, Raza K, Sansom DM.

PLoS One. 2015 Jul 2;10(7):e0131539. doi: 10.1371/journal.pone.0131539. eCollection 2015.

16.

Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS).

Dancer RC, Parekh D, Lax S, D'Souza V, Zheng S, Bassford CR, Park D, Bartis DG, Mahida R, Turner AM, Sapey E, Wei W, Naidu B, Stewart PM, Fraser WD, Christopher KB, Cooper MS, Gao F, Sansom DM, Martineau AR, Perkins GD, Thickett DR.

Thorax. 2015 Jul;70(7):617-24. doi: 10.1136/thoraxjnl-2014-206680. Epub 2015 Apr 22.

17.

A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.

Hou TZ, Qureshi OS, Wang CJ, Baker J, Young SP, Walker LS, Sansom DM.

J Immunol. 2015 Mar 1;194(5):2148-59. doi: 10.4049/jimmunol.1401876. Epub 2015 Jan 28.

18.

Confusing signals: recent progress in CTLA-4 biology.

Walker LS, Sansom DM.

Trends Immunol. 2015 Feb;36(2):63-70. doi: 10.1016/j.it.2014.12.001. Epub 2015 Jan 9. Review.

19.

CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement.

Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, Kogimtzis A, Kenefeck R, Sansom DM, Walker LS.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):524-9. doi: 10.1073/pnas.1414576112. Epub 2014 Dec 29.

20.

Follicular helper T cell signature in type 1 diabetes.

Kenefeck R, Wang CJ, Kapadi T, Wardzinski L, Attridge K, Clough LE, Heuts F, Kogimtzis A, Patel S, Rosenthal M, Ono M, Sansom DM, Narendran P, Walker LS.

J Clin Invest. 2015 Jan;125(1):292-303. doi: 10.1172/JCI76238. Epub 2014 Dec 8.

21.

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schäffer AA, Grüning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LSK, Sansom DM, Grimbacher B.

Nat Med. 2014 Dec;20(12):1410-1416. doi: 10.1038/nm.3746. Epub 2014 Oct 20.

22.

A transendocytosis perspective on the CD28/CTLA-4 pathway.

Soskic B, Qureshi OS, Hou T, Sansom DM.

Adv Immunol. 2014;124:95-136. doi: 10.1016/B978-0-12-800147-9.00004-2. Review.

PMID:
25175774
23.

Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.

Gardner D, Jeffery LE, Sansom DM.

Am J Transplant. 2014 Sep;14(9):1985-91. doi: 10.1111/ajt.12834. Epub 2014 Aug 6. Review.

24.

Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.

Liaskou E, Jeffery LE, Trivedi PJ, Reynolds GM, Suresh S, Bruns T, Adams DH, Sansom DM, Hirschfield GM.

Gastroenterology. 2014 Jul;147(1):221-232.e7. doi: 10.1053/j.gastro.2014.04.003. Epub 2014 Apr 12.

25.

Regulatory T cells and COPD.

Dancer R, Sansom DM.

Thorax. 2013 Dec;68(12):1176-8. doi: 10.1136/thoraxjnl-2013-203878. Epub 2013 Oct 21.

PMID:
24149825
26.

Comparison of the intracellular trafficking itinerary of ctla-4 orthologues.

Kaur S, Qureshi OS, Sansom DM.

PLoS One. 2013;8(4):e60903. doi: 10.1371/journal.pone.0060903. Epub 2013 Apr 2.

27.

CD28 costimulation: walking the immunological tightrope.

Sansom DM, Walker LS.

Eur J Immunol. 2013 Jan;43(1):42-5. doi: 10.1002/eji.201243211.

28.

Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses.

Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, Kaur S, Raza K, Sansom DM.

J Immunol. 2012 Dec 1;189(11):5155-64. doi: 10.4049/jimmunol.1200786. Epub 2012 Oct 19.

29.

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.

Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, Qureshi OS, Sansom DM, Walker LS.

J Immunol. 2012 Aug 1;189(3):1118-22. doi: 10.4049/jimmunol.1200972. Epub 2012 Jun 29.

30.

Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation.

Qureshi OS, Kaur S, Hou TZ, Jeffery LE, Poulter NS, Briggs Z, Kenefeck R, Willox AK, Royle SJ, Rappoport JZ, Sansom DM.

J Biol Chem. 2012 Mar 16;287(12):9429-40. doi: 10.1074/jbc.M111.304329. Epub 2012 Jan 19.

31.

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Walker LS, Sansom DM.

Nat Rev Immunol. 2011 Nov 25;11(12):852-63. doi: 10.1038/nri3108.

PMID:
22116087
32.

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM.

Science. 2011 Apr 29;332(6029):600-3. doi: 10.1126/science.1202947. Epub 2011 Apr 7.

33.

Expression and function of the autoimmune regulator (Aire) gene in non-thymic tissue.

Eldershaw SA, Sansom DM, Narendran P.

Clin Exp Immunol. 2011 Mar;163(3):296-308. doi: 10.1111/j.1365-2249.2010.04316.x. Review.

34.

1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3.

Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker LS, Lammas DA, Raza K, Sansom DM.

J Immunol. 2009 Nov 1;183(9):5458-67. doi: 10.4049/jimmunol.0803217.

35.

Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.

Schmidt EM, Wang CJ, Ryan GA, Clough LE, Qureshi OS, Goodall M, Abbas AK, Sharpe AH, Sansom DM, Walker LS.

J Immunol. 2009 Jan 1;182(1):274-82.

36.

Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3.

Zheng Y, Manzotti CN, Burke F, Dussably L, Qureshi O, Walker LS, Sansom DM.

J Immunol. 2008 Aug 1;181(3):1683-91.

37.

Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease.

Hewison M, Burke F, Evans KN, Lammas DA, Sansom DM, Liu P, Modlin RL, Adams JS.

J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):316-21.

PMID:
17368179
38.

The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology.

Sansom DM, Walker LS.

Immunol Rev. 2006 Aug;212:131-48. Review.

PMID:
16903911
39.

Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86.

Manzotti CN, Liu MK, Burke F, Dussably L, Zheng Y, Sansom DM.

Eur J Immunol. 2006 Jun;36(6):1413-22.

40.

Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells.

Mead KI, Zheng Y, Manzotti CN, Perry LC, Liu MK, Burke F, Powner DJ, Wakelam MJ, Sansom DM.

J Immunol. 2005 Apr 15;174(8):4803-11.

41.

CTLA4 gene polymorphism and autoimmunity.

Gough SC, Walker LS, Sansom DM.

Immunol Rev. 2005 Apr;204:102-15. Review.

PMID:
15790353
42.

Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset.

Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT.

Immunology. 2004 May;112(1):38-43.

43.

CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells.

Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM.

J Immunol. 2004 Mar 1;172(5):2778-84.

44.

Identification of a secondary zinc-binding site in staphylococcal enterotoxin C2. Implications for superantigen recognition.

Papageorgiou AC, Baker MD, McLeod JD, Goda SK, Manzotti CN, Sansom DM, Tranter HS, Acharya KR.

J Biol Chem. 2004 Jan 9;279(2):1297-303. Epub 2003 Oct 14.

45.

What's the difference between CD80 and CD86?

Sansom DM, Manzotti CN, Zheng Y.

Trends Immunol. 2003 Jun;24(6):314-9. Review.

PMID:
12810107
46.

Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.

Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, Sansom DM.

Eur J Immunol. 2002 Oct;32(10):2888-96.

47.

Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers.

Toellner KM, Jenkinson WE, Taylor DR, Khan M, Sze DM, Sansom DM, Vinuesa CG, MacLennan IC.

J Exp Med. 2002 Feb 4;195(3):383-9.

48.

CD28, CTLA-4 and their ligands: who does what and to whom?

Sansom DM.

Immunology. 2000 Oct;101(2):169-77. Review. No abstract available.

49.

Lack of activation induced cell death in human T blasts despite CD95L up-regulation: protection from apoptosis by MEK signalling.

Walker LS, McLeod JD, Boulougouris G, Patel YI, Ellwood CN, Hall ND, Sansom DM.

Immunology. 1999 Dec;98(4):569-75.

50.

IL-2-independent activation and proliferation in human T cells induced by CD28.

Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM.

J Immunol. 1999 Aug 15;163(4):1809-16.

Supplemental Content

Loading ...
Support Center